7,278
Views
7
CrossRef citations to date
0
Altmetric
Brief Report

Comparison of the Therapeutic Efficacy of Epoetin Beta and Epoetin Alfa in Maintenance Phase Hemodialysis Patients

, &
Pages 373-375 | Received 13 Oct 2010, Accepted 27 Jan 2011, Published online: 14 Mar 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Muhammad Nadeem Ahsan, Naila Asif, Shafqat Waqar Khanzada, Muhammad Sohaib Asghar, Farah Yasmin, Faran Khalid, Shameen Fareed & Syeda Ghazala Irshad. (2021) Comparative effectiveness of erythropoietin alpha and beta in hemodialysis patients: a single-center prospective observational study. Journal of Community Hospital Internal Medicine Perspectives 11:6, pages 782-786.
Read now

Articles from other publishers (6)

Iman Karimzadeh, Hanieh Rasekh, Ava Karimian, Mojtaba Shabani-Borujeni & Afsaneh Vazin. (2023) Drug Utilization Evaluation of Erythropoietin at a Referral Teaching Hospital in Iran. Advances in Pharmacological and Pharmaceutical Sciences 2023, pages 1-8.
Crossref
PhoebeAnne Mateo Diño-Santos, RachelleC Dela Cruz, CaridadM Santos & AngeloMartin B. Catacutan. (2023) Therapy with erythropoietin-alpha and erythropoietin-beta for anemia of chronic kidney disease in children on maintenance hemodialysis. Asian Journal of Pediatric Nephrology 6:1, pages 2.
Crossref
Zuzana Tóthová, Jana Tomc, Nataša Debeljak & Peter Solár. (2021) STAT5 as a Key Protein of Erythropoietin Signalization. International Journal of Molecular Sciences 22:13, pages 7109.
Crossref
Ben Cowper, Martin Lavén, Birgit Hakkarainen & Ezra Mulugeta. (2020) Glycan analysis of erythropoiesis-stimulating agents. Journal of Pharmaceutical and Biomedical Analysis 180, pages 113031.
Crossref
Nages Nagaratnam, Kujan Nagaratnam & Gary CheukNages Nagaratnam, Kujan Nagaratnam & Gary Cheuk. 2018. Geriatric Diseases. Geriatric Diseases 287 296 .
Nages Nagaratnam, Kujan Nagaratnam & Gary CheukNages Nagaratnam, Kujan Nagaratnam & Gary Cheuk. 2017. Geriatric Diseases. Geriatric Diseases 1 10 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.